Autolus Therapeutics Ltd Asset Resilience Ratio

Latest as of June 2026: 6.13%

Autolus Therapeutics Ltd asset resilience ratio. Autolus Therapeutics Ltd (AUTL) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Autolus Therapeutics Ltd (AUTL) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$30.22 Million

Cash + Short-term Investments

Total Assets

$493.23 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Autolus Therapeutics Ltd (2023–2025)

Asset resilience ratio of Autolus Therapeutics Ltd from 2023 to 2025. This chart shows how Autolus Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Autolus Therapeutics Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Autolus Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Autolus Therapeutics Ltd's balance sheet.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$30.22 Million	6.13%
Total Liquid Assets	$30.22 Million	6.13%

Asset Resilience Insights

Limited Liquidity: Autolus Therapeutics Ltd maintains only 6.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Autolus Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Autolus Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

Autolus Therapeutics Ltd Asset Resilience Ratio by Year (2023–2025)

Autolus Therapeutics Ltd asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	33.37%	$196.58 Million	$589.07 Million	-12.70pp
2024-12-31	46.08%	$360.64 Million	$782.73 Million	--
2023-12-31	0.00%	$0.00	$375.38 Million	--

pp = percentage points

About Autolus Therapeutics Ltd

NASDAQ:AUTL USA Biotechnology

Market Cap

$404.57 Million

Market Cap Rank

#13003 Global

#3206 in USA

Share Price

$1.52

Change (1 day)

-3.80%

52-Week Range

$1.21 - $2.54

All Time High

$48.01